Article Text

other Versions

PDF
Synovial immunopathological changes associated with successful abatacept therapy in a case of severe refractory psoriatic arthritis
  1. Juan D Cañete1,
  2. Raquel Celis1,
  3. Victoria Hernández1,
  4. José Luis Pablos2,
  5. Raimon Sanmartí1
  1. 1Arthritis Unit, Rheumatology Department, Hospital Clínic and Institut d’Investigacions Biomèdiques Agustí Pí I Sunyer (IDIBAPS), Barcelona, Spain
  2. 2Unidad de Investigación, Servicio de Reumatología, Hospital 12 de Octubre, Madrid, Spain
  1. Correspondence to Dr Juan D Cañete, Arthritis Unit, Rheumatology Department, Hospital Clinic de Barcelona and IDIBAPS, Villarroel, 170, 08036 Barcelona, Spain; jcanete{at}clinic.ub.es

Statistics from Altmetric.com

The overlapping characteristics of rheumatoid arthritis and psoriatic arthritis (PsA) in terms of T-cell and macrophage infiltration and cytokine patterns suggest that targeted therapies could have a similar effect in both diseases.1 Tumour necrosis factor alpha (TNFα) blockers have shown efficacy in PsA, but a significant proportion of patients do not respond or are intolerant to these drugs.2 In these patients, agents blocking T-cell activation are a potential therapeutic option. Preliminary data have shown efficacy of abatacept in psoriasis vulgaris3 and spondyloarthropathy.4 However, data on the effects of abatacept in PsA are lacking. We describe the clinical and immunopathological effects of abatacept in a patient with PsA refractory to TNFα therapy. …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.